Home news Type 2 Diabetes pipeline Market Development by Companies 2017

Type 2 Diabetes pipeline Market Development by Companies 2017


Type 2 DiabetesType 2 Diabetes pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Get a discount on this report at


Companies Involved in Type 2 Diabetes Development are 4P Therapeutics LLC, Addex Therapeutics Ltd, Adocia, Advinus Therapeutics Ltd, Aegis Therapeutics LLC, AFFiRiS AG, Alize Pharma SAS, Allergan Plc, Alteogen Inc, Amarantus Bioscience Holdings Inc, Amgen Inc, Anchor Therapeutics Inc, AntriaBio Inc, Aphios Corp, Araim Pharmaceuticals Inc, Arena Pharmaceuticals Inc, Arisaph Pharmaceuticals Inc, ArisGen SA, Astellas Pharma Inc, AstraZeneca Plc, AusBio Ltd, Avadel Pharmaceuticals Plc, Bayer AG, Beta-Cell NV, Betagenon AB, Betta Pharmaceuticals Co Ltd, Biocon Ltd, BioLingus AG, BioRestorative Therapies Inc, Biozeus, Biscayne Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Boston Therapeutics Inc, Braasch Biotech LLC, Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, Cadila Pharmaceuticals Ltd, Cardax Inc, Carmot Therapeutics Inc, Celon Pharma SA, Chipscreen Biosciences Ltd, Chong Kun Dang Pharmaceutical Corp, CJ HealthCare Corp, CohBar Inc, Concenter BioPharma Silkim Ltd, ConjuChem LLC, Connexios Life Sciences Pvt Ltd, ConSynance Therapeutics Inc, Corium International Inc, CSL Ltd, CureDM Inc, CymaBay Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, Dance Biopharm Inc, Delpor Inc, Diabetology (Products) Ltd, DiaMedica Therapeutics Inc, Diamyd Medical AB, Diasome Pharmaceuticals Inc, DiscoveryBiomed Inc, DNJ Pharma Inc, Dong-A Socio Holdings Co Ltd, Elcelyx Therapeutics Inc, Eli Lilly and Company, Enteris BioPharma Inc, Enzo Biochem Inc, Epichem Pty Ltd, Esperion Therapeutics Inc, Eternygen GmbH, Evotec AG, F. Hoffmann-La Roche Ltd, Generex Biotechnology Corp, Genexine Inc, Genfit SA, Genmedica Therapeutics SL, Genovate Biotechnology Co LTD, Geropharm LLC, Gilead Sciences Inc, GlaxoSmithKline Plc, Glide Pharmaceutical Technologies Ltd, Glucox Biotech AB, GW Pharmaceuticals Plc, Hadasit Medical Research Services & Development Ltd, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Heptares Therapeutics Ltd, HitGen LTD, Hyundai Pharmaceutical Co Ltd, Immuron Ltd, Innopharmax Inc, Innovative Targeting Solutions Inc, Intarcia Therapeutics Inc, Intas Pharmaceuticals Ltd, Integral Molecular Inc, Intercept Pharmaceuticals Inc, Intrexon Corp, Ionis Pharmaceuticals Inc, Ironwood Pharmaceuticals Inc, Islet Sciences Inc, Japan Tobacco Inc, Jeil Pharmaceutical Co Ltd, Jenrin Discovery Inc, JHL Biotech Inc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Kadimastem Ltd, Kadmon Corp LLC, Kareus Therapeutics SA, Kissei Pharmaceutical Co Ltd, Lead Discovery Center GmbH, Leading BioSciences Inc, Lexicon Pharmaceuticals Inc, LG Chem, Ltd., Ligand Pharmaceuticals Inc, LipimetiX Development Inc, Lonestar Heart Inc, Longevity Biotech Inc,  Luye Pharma Group Ltd, Magnus Life Ltd, Medesis Pharma SA, Medestea Research & Production SpA, MedImmune LLC , Medlab Clinical Ltd, Melior Discovery Inc, Mellitech SAS, Merck & Co Inc, Mesoblast Ltd, Metabolic Solutions Development Company LLC, Metabolys SAS, Metacrine Inc, Mitsubishi Tanabe Pharma Corp, Moderna Therapeutics Inc, Naia Ltd, Neurimmune Holding AG, Neurocrine Biosciences Inc, NGM Biopharmaceuticals Inc, Nordic Bioscience A/S, Novapeutics LLC, Novartis AG, NovaTarg Therapeutics Inc, Novo Nordisk A/S, Noxxon Pharma AG, Omeros Corp, OPKO Biologics Ltd, OPKO Health Inc, Oramed Pharmaceuticals Inc, Paras Biopharmaceuticals Finland Oy, Peptron Inc, Pfizer Inc, PharmaCyte Biotech Inc, PharmaIN Corp, Pila Pharma AB, Poxel SA, Prometheon Pharma LLC, ProMetic Life Sciences Inc, Purzer Pharmaceutical Co Ltd, Reata Pharmaceuticals Inc, ReCyte Therapeutics Inc, reMYND NV, Renova Therapeutics Inc, Reset Therapeutics Inc, Saniona AB, Sanofi, Sanwa Kagaku Kenkyusho Co Ltd, SATT Conectus Alsace SAS, SBI Pharmaceuticals Co Ltd, Seres Therapeutics Inc, Serodus ASA, Serometrix LLC, Sevion Therapeutics Inc, Shenzhen HighTide Biopharmaceutical Ltd, Shionogi & Co Ltd, Sihuan Pharmaceutical Holdings Group Ltd, Sirona Biochem Corp, SJT Molecular Research SL, SK Chemicals Co Ltd, Sprint Bioscience AB, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Company Ltd, Tasly Pharmaceutical Group Co Ltd, Teijin Pharma Ltd, The Medicines Company, Theracos Inc, Thermalin Diabetes LLC, Toray Industries Inc, Torrent Pharmaceuticals Ltd, Transgene Biotek Ltd, TTY Biopharm Company Ltd, Uni-Bio Science Group Ltd, Valeant Pharmaceuticals International Inc, ViaCyte Inc, Vichem Chemie Research Ltd, Vicore Pharma AB, Viking Therapeutics Inc, Vivus Inc, vTv Therapeutics Inc, Vybion Inc, XBiotech Inc, Xenetic Biosciences Inc, XL-protein GmbH, XOMA Corp, XuanZhu Pharma Co Ltd, Yuhan Corp, Yungjin Pharm Co Ltd, Zafgen Inc, Zealand Pharma AS, Zensun (Shanghai) Sci & Tech Co Ltd, Zydus Cadila Healthcare Ltd”

The Type 2 Diabetes pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6 respectively.

Sample copy is available at


Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes. The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Type 2 Diabetes therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Please enter your comment!
Please enter your name here